(Circulation. 2000;101:1249.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From The Institute of Clinical Medicine I (L.I., F.V.) and Clinical Surgery II (E.S.), University "La Sapienza," Rome, Italy; and the Department of Pathology (A.M., L.G.S.), University "Tor Vergata," Rome, Italy.
Correspondence to Prof Francesco Violi, Istituto di I Clinica Medica, Policlinico Umberto I, Via Del Policlinico, 00185 Roma, Italy. E-mail violi{at}uniroma1.it
| Abstract |
|---|
|
|
|---|
Methods and ResultsIn 7 patients with previous transient
ischemic attack or stroke and critical (>70%) carotid
stenosis, autologous native [125I]-labeled LDL or
[125I]-labeled human serum albumin were injected
24 to 72 hours before endarterectomy. Carotid
specimens obtained at endarterectomy were
analyzed by autoradiography and
immunohistochemistry. Autoradiographic study showed that
LDL was localized prevalently in the foam cells of atherosclerotic
plaques, whereas the accumulation in the lipid core was negligible.
Immunohistochemistry revealed that foam cells that had accumulated
radiolabeled LDL were mostly CD68 positive, whereas a small number were
-actin positive. No accumulation of the radiotracer was detected in
atherosclerotic plaques after injection of radiolabeled human serum
albumin. In 3 patients treated for 4 weeks with vitamin E (900
mg/d), an almost complete suppression of radiolabeled LDL uptake by
macrophages was observed.
ConclusionsThis study shows that circulating LDL rapidly accumulates in human atherosclerotic plaque. The prevalent accumulation of LDL by macrophages provides strong support to the hypothesis that these cells play a crucial role in the pathogenesis of atherosclerosis.
Key Words: atherosclerosis lipoproteins stenosis plaque oxidant stress
| Introduction |
|---|
|
|
|---|
According to the oxidative-modification hypothesis, LDL would initially accumulate in the subendothelial space and, after oxidative changes induced by resident cells such as endothelial cells, macrophages, or smooth muscle cells, would be taken up by macrophages through the scavenger receptor. However, the temporal sequence of these events has never been demonstrated in human beings. To test this hypothesis in human atherosclerosis, we analyzed in patients with critical (>70%) carotid stenosis whether injected radiolabeled autologous native LDL accumulated in the carotid atherosclerotic plaque. To this purpose, 24 to 72 hours after injection of radiolabeled LDL, atherosclerotic specimens were obtained at endarterectomy and analyzed by autoradiography and immunohistochemical autoradiography. In the present study, we demonstrated that circulating LDL accumulates prevalently in the monocyte-macrophages of human atherosclerotic plaque and that vitamin E supplementation prevents it.
| Methods |
|---|
|
|
|---|
-tocopherol,
-tocopherol acetate,
poly-L-lysine, bicinchoninic acid, and Sephadex G25 were
from Sigma Chemical Co (Sigma-Aldrich); and carrier-free Na
125I was from Amersham International Ltd. Human
serum albumin, 20% solution, was from Centeon (Centeon SpA).
All other reagents were of the highest grade available from
Merck.
Preparation of LDL
LDL (density 1.025 to 1.050 g/mL) obtained from human plasma was
processed under sterile conditions to minimize exposure to endotoxin.
To minimize oxidation, LDL was prepared in the presence of EDTA and by
fast sequential flotation ultracentrifugation at
100 000 rpm in an Optima TLX Ultracentrifuge (Beckman) with a
TLA 100.4 rotor. LDL was collected by upward fractionation to minimize
albumin contamination.7 The purity of LDL
evaluated by agarose gel electrophoresis was >98%. Before labeling,
the purified lipoproteins were desalted by Sephadex G25
chromatography, at 4°C, with saline used as the
exchanging solution. Protein concentration was determined by the
bicinchoninic acid method.8 LDL and human serum
albumin were radiolabeled with 125I by
use of the iodine monochloride method.9 After labeling,
the proteins were passed through a Sephadex G25 column to remove free
125I, with 0.1 mol/L sodium bicarbonate in 0.9%
NaCl (pH 8) used as the exchanging buffer. Before injection,
radiolabeled proteins were sterilized by passage through a 0.22-µm
Millipore filter. LDL samples were assayed for oxidation by measuring
the levels of thiobarbituric acidreactive substances, lipid
hydroperoxides, and electrophoretic mobility as previously
described.10 Before injection, both LDL and human serum
albumin were always tested for endotoxin contamination by the
Limulus amebocytes lysate assay, as previously
described.11 Final endotoxin contamination was always
<0.02 U/mg LDL cholesterol.
In Vivo Studies
We studied 10 patients (4 women and 6 men, ages 68 to 74 years)
who were eligible for endarterectomy (previous
transient ischemic attack or stroke and carotid
stenosis >70%). Informed consent was obtained from all
patients before the study. All procedures were approved by the local
human ethics committee. Blood was withdrawn from each patient after
overnight fasting and immediately processed for LDL separation and
radiolabeling with 125I as described above. Among
7 patients injected with 125I-LDL, 3 were treated
with 900 mg/d vitamin E for 4 weeks before
endarterectomy. Radiolabeled autologous LDL were
bolus-injected within 24 hours from blood withdrawal. Commercial human
albumin was adopted as control with the same LDL protocol used
for radiolabeling and injection. The amount of radiolabeled protein
injected was 5 µCi of [125I]-LDL or 10 µCi
of [125I]-albumin. No side effects were
observed in patients after injection of radiolabeled proteins. Patients
underwent surgery 24 to 72 hours after radiolabeled protein injection.
Immediately after surgery, endarterectomy specimens
were rinsed twice with cold PBS containing EDTA to remove contaminated
blood.
Autoradiography
Light microscopy autoradiographic studies were
carried out on 4 carotid endarterectomy specimens
obtained from patients injected with autologous
[125I]-native LDL and 3 carotid specimens
obtained from patients injected with
[125I]-albumin as control. Patients
injected with native LDL (4 men and 3 women, ages 70 to 74 years) or
human serum albumin (2 men and 1 woman, ages 68 to 70 years)
had comparable prevalence of risk factors such as diabetes,
hypercholesterolemia, hypertension, or smoking.
Total cholesterol, LDL cholesterol, and HDL
cholesterol plasma levels in patients treated with vitamin
E were comparable to those of control patients.
After surgical procedures, samples were immediately fixed in 0.1 mol/L phosphate buffer, pH 7.4, containing 10% (wt/vol) formaldehyde and 0.5% (wt/vol) glutaraldehyde. After decalcification, if necessary, the specimens were sliced transversally every 3 mm and embedded in paraffin.
Five sections per slice (3 µm thick, mean 50 sections per plaque) were processed for autoradiographic studies. Before autoradiographic procedures, 2 sections per slice were processed immunohistochemically to characterize the cell types present within the plaque.12 All samples were processed for autoradiography within 72 hours of the surgical procedure.
For autoradiography, sections were coated with Ilford K2 emulsion (Ilford Ltd) diluted 1:1 with 1% glycerol. After 6 weeks of exposure at 4°C in light-proof boxes containing silica gel, sections were developed in Kodak D-19 (Kodak-Pathé) and then cleared in Ilford Hypam, washed in water, and stained with hematoxylin and eosin.
In each section, silver grain density over plaque cells and
interstitial tissue was obtained by determining the number
of silver grains per surface area by an oil-immersion objective.
Surface area was measured with the aid of Scion Image software. To
quantify the intracellular radiolabeled LDL content, we randomly
analyzed 20 macrophages corresponding to
62 000
µm2, which were present in the cap region
of the plaque of each subject. Values were expressed as number of
silver grains (mean±SE)/100 µm2
cytoplasm. Grain density over plaque structures was
corrected for background radiation, which was measured in
a similar manner over areas of the slides devoid of vascular
tissue. Background radiation had a mean value of 0.95
grains/100 µm2.
Immunohistochemical Study
Two serial sections cut from paraffin blocks were mounted on
slides previously treated with poly-L-lysine solution. To
characterize the phenotype of the cells that were positive in
the autoradiography analysis, sections were
incubated with the monoclonal primary antibody anti-CD68 (anti-human
monocyte/macrophages) (Dakopatts)13 and the
anti
-smooth muscle actin antibody (Dakopatts), which recognizes
vascular smooth muscle cells.14 These antibodies were used
as previously described.12
Plasma Vitamin E Assay
After overnight fasting, blood samples were taken into tubes
containing heparin and centrifuged at 500g for 10
minutes to obtain plasma. The plasma was stored at -20°C until
assay. Plasma vitamin E was measured by high-performance liquid
chromatography with UV detection, and vitamin E acetate
was used as the internal standard.15
Statistical Analysis
Data analysis was carried out by ANOVA and by Students
t test. Significance was accepted at the level of
P<0.05.
| Results |
|---|
|
|
|---|
The plaques were composed of a great number of inflammatory
cells, including monocyte/macrophages, CD68-positive cells, and
lymphocytes, principally localized in the shoulder and cap of the
plaque. Cell density in the cap and shoulder of the plaque was similar
among the 3 groups of patients. The CD68-positive cells were mainly
composed of foam cells with a round, often eccentric nucleus, and the
cytoplasm was filled entirely with lipid droplets. A small number of
CD68-positive cells were monocytes. A few muscular foam cells,
preferentially localized in the cap region, also were present.
These foam cells were
-smooth muscle actin positive and were
featured as elongated cells with a fusiform nucleus; the cytoplasm was
largely or entirely filled by lipid droplets.
After intravenous injection, autologous radiolabeled
native LDL was detected in atherosclerotic plaques by light microscopy
autoradiography. Deposition of radioactivity was
detected in specimens obtained 24 hours after LDL injection (Figure 1
) and was seen in samples obtained 72
hours after LDL injection (not shown).
|
Developed silver grains in numbers exceeding that of
the background were always present over the foam cells of the cap
and shoulder. The grain density over the foam cells ranged from 5.88 to
9.05/100 µm2, compared with 0.95/100
µm2 of background. Radiolabeled LDL was
observed within the cytoplasm, whereas extracellular deposition was
negligible (Figure 1
, A and B). Most of the labeled foam cells
were CD68 positive (Figure 1C
and Figure 2
), whereas few cells were
-actin
positive (Figure 1D
and 2
).
|
No difference in radiolabeling was observed in the lipid core,
compared with the grain density of background (Figure 1E
).
Localization of radioactivity within cells but not in the lipid
core suggested that LDL distribution within the atherosclerotic plaque
was specific. This suggestion was corroborated by demonstrating that
very low radioactivity was accumulated within the atherosclerotic
plaque after intravenous injection of radiolabeled human
serum albumin (Figure 1F
). However, albumin
radioactivity was comparable to the background radiation seen with LDL
infusion, and the overall radioactivity accumulated with
albumin infusion was equally distributed in cells and
extracellular areas.
Because native LDL generally does not accumulate in macrophage-derived foam cells,17 our findings would imply that native LDL has probably undergone oxidative modification and was then taken up by macrophages. We could exclude that LDL underwent oxidative modification in vitro because after the radiolabeling, no formation of malondialdehyde equivalents and lipid hydroperoxides was detected. Furthermore, no electrophoretic mobility modification was observed in radiolabeled LDL compared with freshly separated LDL (not shown).
To further explore this hypothesis, we measured
macrophage LDL uptake in carotid plaques taken from patients
given vitamin E (900 mg/d) for 4 weeks before procedure. We found that
vitamin Etreated patients had significantly lower radiolabeled LDL
content than did untreated patients (Figure 3
). Serum vitamin E was 28±6.1
µmol/L at baseline and increased to 54±8.6 after vitamin E
supplementation.
|
| Discussion |
|---|
|
|
|---|
On the basis of current knowledge, it is believed that macrophages express abundant scavenger receptors that recognize only modified LDL, such as oxidized LDL but not native LDL.1 2 17 Thus it could be suggested that intracellular deposition of radiolabeled LDL after intravenous injection occurred as a consequence of oxidative modification of LDL.
Although it seems logical that accumulation of LDL within the foam cells may be explained only by assuming the oxidative change of LDL, it remains to be established where and how LDL is oxidized, that is, before or after crossing the vessel wall. As far as the first point is concerned, we can reasonably exclude that circulating LDL was already oxidized before crossing the arterial wall. We used a fast procedure to separate LDL from plasma, and LDL did not show any sign of oxidative modification before injection. The possibility of oxidation after injection, during circulation of LDL in the blood compartment and before crossing the vessel wall, could be excluded considering the abundance of antioxidants present in plasma.22 From these data, it can be deduced that LDL was not oxidized in the circulation system but very likely after crossing the arterial wall. Further support for the hypothesis that LDL uptake by macrophages occurred as a consequence of oxidation was provided by the interventional study with antioxidants. Thus we observed that after treatment with vitamin E, uptake of radiolabeled LDL by plaque-resident macrophages was almost completely suppressed.
This suggestion is strongly corroborated by an experimental study in which Calara et al23 evaluated the localization of native radiolabeled LDL after intravenous or intraperitoneal injection in Sprague-Dawley rats. With the use of antibodies against Apolipoprotein B and epitopes present on oxidized LDL, these investigators localized LDL and oxidized LDL in the arterial endothelium and media within 6 hours of injection; accumulation peaked at 12 hours for native LDL and 24 hours for oxidized LDL. These investigators also demonstrated a reduced number of epitopes present on oxidized LDL in the case of injection of LDL enriched by the antioxidant probucol. Our findings showing that vitamin E inhibits LDL uptake by macrophages in atherosclerotic plaque might have potential clinical implications because they represent an important approach to the prevention of progression of atherosclerosis. Consistent with this suggestion is the demonstration that vitamin E supplementation reduces atherosclerotic lesions in an experimental model of Apolipoprotein E deficient mice. Praticò et al24 found that this atherosclerotic model is associated with enhanced oxidative stress and that vitamin E supplementation reduces aortic lesions coincidentally with inhibition of oxidative stress.
In conclusion, we showed that circulating LDL accumulates within the foam cells of human atherosclerotic plaque. This process is likely to occur after oxidative modification of LDL within the vessel wall, but further study is necessary to fully elucidate the exact sequence of events leading to intracellular LDL accumulation.
| Acknowledgments |
|---|
Received April 28, 1999; revision received September 20, 1999; accepted October 7, 1999.
| References |
|---|
|
|
|---|
2. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;334:793795.
3.
Daugherty A, Zwiefel BS, Sobel BE, Schonfeld G.
Isolation and characterization of low density lipoproteins from
atherosclerotic vascular tissue of Watanabe heritable
hyperlipidemic rabbits.
Arteriosclerosis. 1988;8:768777.
4. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:10861095.
5.
Haberland ME, Fong D, Chen L.
Malondialdehyde-altered protein occurs in atheroma of
Watanabe heritable hyperlipidemic rabbits.
Science. 1988;241:215218.
6. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela R, Salonen K, Nyyssonen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883887.[Medline] [Order article via Infotrieve]
7. Chung BH, Segrest JP, Ray JR, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT. Single vertical spin gradient ultracentrifugation. Methods Enzymol. 1986;128:181209.[Medline] [Order article via Infotrieve]
8. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klent DJ. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:7685.[Medline] [Order article via Infotrieve]
9. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins, I: preliminary in vitro and in vivo observations. Biochem Biophys Acta. 1972;260:212221.[Medline] [Order article via Infotrieve]
10. Iuliano L, Colavita AR, Camastra C, Bello V, Quintarelli C, Alessandroni M, Piovella F, Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119:14381446.[Medline] [Order article via Infotrieve]
11.
Praticò D, FitzGerald GA. Generation of
8-epi-prostaglandin F2
by human
monocytes: discriminate production by reactive oxygen species
and prostaglandin endoperoxide synthase-2.
J Biol Chem. 1996;271:89198924.
12. Praticò D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Maclouf J, Violi F, FitzGerald GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100:20282034.[Medline] [Order article via Infotrieve]
13. Pulford KAF, Rigney EM, Miclem KJ, Jones M, Stross WP, Gatter KC, Mason DY. KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol. 1989;42:1421.
14.
Skalli O, Ropraz P, Trzeciak A, Benzonana G,
Gillesen D, Gabbiani G. A monoclonal antibody against alpha-smooth
muscle actin: a new probe for smooth muscle differentiation.
J Cell Biol. 1986;103:27872796.
15. Praticò D, Iuliano L, Basili S, Ferro D, Camastra C, Cordova C, FitzGerald GA, Violi F. Enhanced lipid peroxidation in hepatic cirrhosis. J Invest Med. 1998;46:5157.[Medline] [Order article via Infotrieve]
16.
Stary HC, Chandler AB, Dinsmore RE, Fuster V,
Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A
definition of advanced types of atherosclerotic lesions and a
histological classification of
atherosclerosis: a report from the Committee on
Vascular Lesions of the Council on Atherosclerosis,
American Heart Association. Circulation. 1995;92:13551374.
17. Brown MS, Goldestein JL. Lipoprotein metabolism in the macrophage: implication for cholesterol deposition in atherosclerosis. Ann Rev Biochem. 1983;12:223261.
18.
Lees AM, Lees RS, Schoen FJ, Isaacsohn JL,
Fischman AJ, McKusick KA, Strauss W. Imaging human
atherosclerosis with
99mTc-labeled low density lipoproteins.
Arteriosclerosis. 1988;8:461470.
19. Iuliano L, Signore A, Vallabjosula S, Colavita AR, Camastra C, Ronga G, Alessandri C, Sbarigia C, Fiorani P, Violi F. Preparation and biodistribution of 99technetium labeled oxidized LDL in man. Atherosclerosis. 1996;126:131141.[Medline] [Order article via Infotrieve]
20. Napoli C, DArmiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. J Clin Invest. 1997;100:26802690.[Medline] [Order article via Infotrieve]
21.
Gotto AM. Cholesterol management in
theory and practice. Circulation. 1997;96:44244430.
22. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A. 1988;85:97489752.
23.
Calara F, Dimayuga P, Niemann A, Thyberg J,
Diczfalusy U, Witztum JL, Palinski W, Shah K, Cercek B, Nilsson J,
Regnström J. An animal model to study local oxidation of LDL and
its biological effects in the arterial wall.
Arterioscler Thromb Vasc Biol. 1998;18:884893.
24. Praticò D, Tangirala RK, Rader D, Rokach J, FitzGerald GA. Vitamin e suppresses isoprostane generation in vivo and reduces atherosclerosis in Apo E-deficient mice. Nat Med. 1998;4:11891192.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. M. Kwee, R. J. van Oostenbrugge, L. Hofstra, G. J. Teule, J.M.A. van Engelshoven, W. H. Mess, and M. E. Kooi Identifying vulnerable carotid plaques by noninvasive imaging Neurology, June 10, 2008; 70(24_Part_2): 2401 - 2409. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Violi and R. Cangemi Statin Treatment as a Confounding Factor in Human Trials with Vitamin E J. Nutr., June 1, 2008; 138(6): 1179 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ogier, A. Klein, V. Deckert, A. Athias, G. Bessede, N. Le Guern, L. Lagrost, and C. Desrumaux Cholesterol Accumulation Is Increased in Macrophages of Phospholipid Transfer Protein-Deficient Mice: Normalization by Dietary Alpha-Tocopherol Supplementation Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2407 - 2412. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Martino, P. Pignatelli, E. Martino, F. Morrone, R. Carnevale, S. Di Santo, B. Buchetti, L. Loffredo, and F. Violi Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1974 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Carnevale, P. Pignatelli, L. Lenti, B. Buchetti, V. Sanguigni, S. Di Santo, and F. Violi LDL are oxidatively modified by platelets via GP91phox and accumulate in human monocytes FASEB J, March 1, 2007; 21(3): 927 - 934. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pignatelli, L. Lenti, V. Sanguigni, G. Frati, I. Simeoni, P. P. Gazzaniga, F. M. Pulcinelli, and F. Violi Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H41 - H48. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Violi, F. Micheletta, and L. Iuliano Antioxidants and atherosclerosis Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B17 - B21. [Abstract] [PDF] |
||||
![]() |
L. Iuliano, F. Micheletta, F. Violi, L.G. Spagnoli, E. M. Lonn, S. Yusuf, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, et al. Effect of Ramipril and Vitamin E on Atherosclerosis Response Circulation, January 15, 2002; 105 (2): e5 - e6. [Full Text] [PDF] |
||||
![]() |
R. RICCIARELLI, J.-M. ZINGG, and A. AZZI Vitamin E: protective role of a Janus molecule FASEB J, November 1, 2001; 15(13): 2314 - 2325. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. A. Fayad and V. Fuster Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque Circ. Res., August 17, 2001; 89(4): 305 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tsimikas and J. L. Witztum Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk Circulation, April 17, 2001; 103(15): 1930 - 1932. [Full Text] [PDF] |
||||
![]() |
M. Meydani Vitamin E and Atherosclerosis: Beyond Prevention of LDL Oxidation J. Nutr., February 1, 2001; 131(2): 366S - 368. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |